Earlier this week Vaxcyte (PCVX) shared an update on its VAX-31 trial results, which are quite promising. The stock popped nearly 50% on the news, sending shares to an all-time high of $115/share. VAX-31 is the company’s pneumococcal conjugate vaccine. This disease can contribute to more serious illnesses such as pneumonia, meningitis, and various [...]
Sarepta Therapeutics (SRPT) announced late Thursday it had gained FDA approval for its treatment designed to target a rare genetic disease known as Duchenne muscular dystrophy (DMD). This condition causes progressive weakness, predominantly in boys, and is caused by a lack of key protein dystrophin. It has no known cure at this time. The [...]
Shares of Moderna (MRNA) climbed 13% in yesterday’s trading session after being upgraded to a buy at Oppenheimer. The stock fell a bit in Wednesday’s trading session, but has since settled at around even on the day. Hartaj Singh and a team of analysts see dramatic upside potential over the next few years for [...]
Gene therapy developer Rocket Pharmaceuticals (RCKT) investors woke up in delight as shares skyrocketed in Wednesday morning’s pre-market trading session. When the bell sounded, the stock continued its trajectory and it currently sits 38% higher than it last closed at. This comes after the company announced that it has aligned with the Food and [...]
Recursion Pharmaceuticals (RXRX) just got an endorsement from one of Wall Street’s hottest stocks at the moment, and as such, has earned the attention of analysts, retail investors, and professionals alike. After securing a $50 million investment from Nvidia (NVDA), the RXRX shot up more than 76%. The two companies are more alike than [...]
Protalix BioTherapeutics, Inc. (PLX: NYSE AMEX and Tel Aviv Stock Exchange) is headquartered in Carmiel, Israel with an office in Hackensack, NJ, with a total of 197 employees. Protalix Ltd. was incorporated in 1993. It became a U.S public company on December 31, 2006. PLX is a biopharmaceutical company that develops, produces and commercializes [...]
Last week Moderna (MRNA) announced a licensing deal with Generation Bio that they hope will allow them to overcome the losses they’re facing now that the COVID-19 pandemic has come and gone. And as a result of this deal, Generation Bio (GBIO) gained 34% in the past week of trading. The partnership will have [...]
